Dhifaf Sarhan - Publications

Oncology and Pathology Karolinska Instituet 

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Razaghi A, Poorebrahim M, Sarhan D, Björnstedt M. Selenium stimulates the antitumour immunity: Insights to future research. European Journal of Cancer (Oxford, England : 1990). 155: 256-267. PMID 34392068 DOI: 10.1016/j.ejca.2021.07.013  0.08
2021 Chen Z, Yang Y, Neo SY, Shi H, Chen Y, Wagner AK, Larsson K, Tong L, Jakobsson PJ, Alici E, Wu J, Cao Y, Wang K, Liu LL, Mao Y, ... Sarhan D, et al. Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25 /CD54 NK cells. Embo Reports. e51329. PMID 33480074 DOI: 10.15252/embr.202051329  1
2020 Evren E, Ringqvist E, Tripathi KP, Sleiers N, Rives IC, Alisjahbana A, Gao Y, Sarhan D, Halle T, Sorini C, Lepzien R, Marquardt N, Michaëlsson J, Smed-Sörensen A, Botling J, et al. Distinct developmental pathways from blood monocytes generate human lung macrophage diversity. Immunity. PMID 33382972 DOI: 10.1016/j.immuni.2020.12.003  1
2020 La Fleur L, Botling J, He F, Pelicano C, Zhou C, He C, Palano G, Mezheyeuski A, Micke P, Ravetch JV, Karlsson MCI, Sarhan D. Targeting MARCO and IL-37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function. Cancer Research. PMID 33293426 DOI: 10.1158/0008-5472.CAN-20-1885  1
2020 Eisinger S, Sarhan D, Boura VF, Ibarlucea-Benitez I, Tyystjärvi S, Oliynyk G, Arsenian-Henriksson M, Lane D, Wikström SL, Kiessling R, Virgilio T, Gonzalez SF, Kaczynska D, Kanatani S, Daskalaki E, et al. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 33229588 DOI: 10.1073/pnas.2015343117  1
2020 Sarhan D, Wang J, Sunil Arvindam U, Hallstrom C, Verneris MR, Grzywacz B, Warlick E, Blazar BR, Miller JS. Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. Jci Insight. PMID 32045384 DOI: 10.1172/Jci.Insight.130155  1
2019 Sarhan D, Miller JS. Assessing Canonical and Adaptive Natural Killer Cell Function in Suppression Assays In Vitro. Methods in Molecular Biology (Clifton, N.J.). 1913: 153-166. PMID 30666605 DOI: 10.1007/978-1-4939-8979-9_11  1
2018 Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS. Adaptive NK cells resist regulatory T cell suppression driven by IL-37. Cancer Immunology Research. PMID 29784636 DOI: 10.1158/2326-6066.Cir-17-0498  1
2018 de Witte MA, Sarhan D, Davis Z, Felices M, Vallera DA, Hinderlie P, Curtsinger J, Cooley S, Wagner J, Kuball J, Miller JS. Early Reconstitution of NK and Γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29505821 DOI: 10.1016/J.Bbmt.2018.02.023  1
2017 Bachanova V, Sarhan D, DeFor TE, Cooley S, Panoskaltsis-Mortari A, Blazar BR, Curtsinger JM, Burns L, Weisdorf DJ, Miller JS. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunology, Immunotherapy : Cii. PMID 29218366 DOI: 10.1007/S00262-017-2100-1  1
2017 Sarhan D, Leijonhufvud C, Murray S, Witt K, Seitz C, Wallerius M, Xie H, Ullén A, Harmenberg U, Lidbrink E, Rolny C, Andersson J, Lundqvist A. Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer. Oncoimmunology. 6: e1338238. PMID 28920001 DOI: 10.1080/2162402X.2017.1338238  1
2017 Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno SK, Tuininga K, Dougherty P, McCullar V, Howard P, Sarhan D, Taras E, Schlums H, et al. GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Research. PMID 28790065 DOI: 10.1158/0008-5472.Can-17-0799  1
2017 Lövgren T, Sarhan D, Truxová I, Choudhary B, Maas R, Melief J, Nyström M, Edbäck U, Vermeij R, Scurti G, Nishimura M, Masucci G, Karlsson-Parra A, Lundqvist A, Adamson L, et al. Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists. Cancer Immunology, Immunotherapy : Cii. PMID 28601925 DOI: 10.1007/S00262-017-2029-4  1
2017 Cichocki F, Valamehr B, Bjordahl R, Zhang B, Sarhan D, Cooley S, Blazar B, Rezner B, Rogers P, Green C, Abbot S, Shoemaker D, Wolchko S, Miller JS. Abstract 3752: FATE-NK100: A novel NK cell-mediated cancer therapy Cancer Research. 77: 3752-3752. DOI: 10.1158/1538-7445.Am2017-3752  1
2016 Luu TT, Ganesan S, Wagner AK, Sarhan D, Meinke S, Garbi N, Hämmerling G, Alici E, Kärre K, Chambers BJ, Höglund P, Kadri N. Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells. Scientific Reports. 6: 37996. PMID 27905484 DOI: 10.1038/Srep37996  1
2016 Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, Verneris MR, Blazar BR, Miller JS. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Research. PMID 27503932 DOI: 10.1158/0008-5472.Can-16-0839  1
2016 Felices M, Sarhan D, Brandt L, Guldevall K, McElmurry R, Lenvik A, Chu S, Tolar J, Taras E, Spellman SR, Warlick ED, Verneris MR, Cooley S, Weisdorf D, Blazar BR, et al. CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics Blood. 128: 4291-4291. DOI: 10.1182/Blood.V128.22.4291.4291  1
2016 Bachanova V, Sarhan D, DeFor TE, Cooley S, Panoskaltsis-Mortari A, Verneris MR, Blazar BR, Curtsinger J, Burns LJ, Weisdorf DJ, Miller JS. Haploidentical Natural Killer Cell Infusion Induces Remission in Non-Hodgkin Lymphoma and Overcomes Resistance to Rituximab Blood. 128: 3030-3030. DOI: 10.1182/Blood.V128.22.3030.3030  1
2016 Cichocki F, Valamehr B, Sarhan D, Zhang B, Cooley S, Verneris MR, Blazar BR, Bjordahl R, Rezner B, Rogers P, Green C, McKenna DH, Shoemaker D, Wolchko S, Miller JS. Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function Blood. 128: 1225-1225. DOI: 10.1182/Blood.V128.22.1225.1225  1
2016 Adamson L, Sarhan D, Choudhary B, Melief J, Nyström M, Edbäck U, Vermeij R, Scurti G, Nishimura M, Lundqvist A, Kiessling R, Lövgren T. Abstract B071: Enhanced IL-12 production and T cell stimulation ability by dendritic cells matured in presence of GMP-grade Toll-like receptor ligands and IFN-γ Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B071  1
2015 Dahlberg CI, Sarhan D, Chrobok M, Duru AD, Alici E. Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Frontiers in Immunology. 6: 605. PMID 26648934 DOI: 10.3389/fimmu.2015.00605  0.01
2015 Sarhan D, Palma M, Mao Y, Adamson L, Kiessling R, Mellstedt H, Österborg A, Lundqvist A. Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β. European Journal of Immunology. 45: 1783-93. PMID 25773885 DOI: 10.1002/Eji.201444885  1
2014 Sarhan D, D'Arcy P, Lundqvist A. Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system. International Journal of Molecular Sciences. 15: 18557-73. PMID 25318057 DOI: 10.3390/Ijms151018557  1
2014 Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4096-106. PMID 24907113 DOI: 10.1158/1078-0432.Ccr-14-0635  1
2013 Sarhan D, Wennerberg E, D'Arcy P, Gurajada D, Linder S, Lundqvist A. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. Cancer Immunology, Immunotherapy : Cii. 62: 1359-68. PMID 23689729 DOI: 10.1007/S00262-013-1439-1  1
2013 Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D'Arcy P, Zhivotovsky B, Childs R, Lundqvist A. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. International Journal of Cancer. 133: 1643-52. PMID 23504627 DOI: 10.1002/Ijc.28163  1
2013 Sarhan D, D'Arcy P, Wennerberg E, Lidén M, Hu J, Winqvist O, Rolny C, Lundqvist A. Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ. European Journal of Immunology. 43: 249-57. PMID 22996291 DOI: 10.1002/Eji.201242735  1
2012 Kiessling R, Okita R, Mougiakakos D, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kono K. Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells. Oncoimmunology. 1: 1200-1201. PMID 23170279 DOI: 10.4161/Onci.20685  1
2012 Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. Journal of Immunology (Baltimore, Md. : 1950). 188: 2136-45. PMID 22301547 DOI: 10.4049/Jimmunol.1102237  1
Show low-probability matches.